Provider Portal
Contact
Generic selectors
Exact matches only
Search in title
Search in content

Patients deserve the best

CIRCULOGENE is the most comprehensive blood-based approach to detecting clinically significant tumor DNA/RNA alterations.  25,000 cancer patients have benefited from our innovative, best-in-class liquid biopsy.  Our novel approach has created unique liquid biopsy tests which aids oncologists to personalize and monitor the patient’s treatment plan with the goal of better outcomes and survival.

CIRCULOGENE begins with a patented Linear In Situ Amplification (LISA) methodology which effectively preserves and extracts fragile RNA. Our use of next-generation sequencing (NGS) and polymerase chain reaction (PCR) instrumentation provides both the breadth of DNA menu and the depth for RNA detection. These two technological advancements are the basis for our best-in-class menu offerings, including TumorClear, ImmunoClear, MSI Complete, and Hereditary Panels.

CIRCULOGENE can complement tissue biopsy as recommended by the International Association for the Study of Lung Cancer (IASLC) for enabling a faster time to treatment, providing the right first-line treatment, and resulting in better patient outcomes.

TumorClear

Including NCCN essential guideline & expert based DNA markers

ImmunoClear

Offering the ONLY plasma cfRNA PD-L1

MSI Complete

Utilizing advanced MSI technology

Hereditary Panels

Understanding a patient’s genetics

Each patient’s cancer is unique, understanding the origins and severity of the cancers aids oncologists to personalize the patient’s treatment plan at the time of diagnosis and throughout their cancer journey.

The CIRCULOGENE Best-in-Class Advantage

CIRCULOGENE begins some tests with a proprietary Linear In Situ Amplification (LISA) enrichment process resulting in enhanced cfRNA yields. By eliminating the need for a purification step, CIRCULOGENE overcomes the limitations associated with sample volume requirements.  The LISA process preserves and extracts fragile cfRNA, enabling fusions and plasma PD-L1 to be effectively detected.

Learn More

Combined Methodologies

CIRCULOGENE utilizes both NGS and PCR to provide a comprehensive and extensive marker portfolio resulting in accurate results. Rather than limiting the analytical process by only performing NGS, the addition of PCR enables other actionable markers found in RNA mutations and fusions. By combining NGS and PCR instrumentation, CIRCULOGENE provides the breadth of DNA menu and the accuracy for RNA detection.
Learn More
Plasma PD-L1

Plasma PD-L1

The use of LISA and PCR enables CIRCULOGENE to provide the only liquid biopsy method to include plasma PD-L1. CIRCULOGENE’s PD-L1 has also been demonstrated to provide valuable information in non-small cell lung cancer (NSCLC) immunotherapy patients.

Learn more

MSI

MSI

CIRCULOGENE utilizes a MSI protocol which consists of eight markers – four of the gold standard markers, plus four novel markers. It has been hypothesized that these eight markers offer greater sensitivity for MSI detection in cancers where the results are otherwise inconclusive or ambiguous.

Learn more

Actionable Reports

Actionable Reports

Our personalized patient reports, highlight the most significant actionable findings. CIRCULOGENE then provides referenced information on current FDA-approved treatment options proven effective for the tumor DNA mutations and RNA fusions identified.

Learn more

CIRCULOGENE News

Back To Top